You just read:

Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA® (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis

News provided by

Abbott

22 Oct, 2012, 16:00 BST